Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              American CryoStem Corporation

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Biofit 2020

              Participation Not Confirmed

              Update your events

              American Cryo Stem Announces: FDA Has Cleared Its Investigational New Drug (IND) for Post-Concussion Syndrome for PhaseII Clinical Trial

              Contact the Supplier

              Lead Product(s): Mesenchymal stem cell

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ATCell

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 23, 2020

              Details:

              The USFDA has cleared American CryoStem's Investigational New Drug (IND) application for Phase I, to develop ATCell™, a proprietary expanded autologous adipose-derived mesenchymal stem cell therapy for the treatment of Post-Concussion Syndrome (PCS).

              Neuronasal

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Biofit 2020

              Participation Not Confirmed

              Update your events

              ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

              Contact the Supplier

              Lead Product(s): N-Acetylcysteine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              Details:

              Neuronasal's potentially ground-breaking proprietary treatment includes the intranasal delivery of low doses of N-acetylcysteine to patients with acute mild traumatic brain injury (mTBI). NAC has the potential to disrupt the deleterious chain of events following mTBI.

              Neuraptive Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Biofit 2020

              Participation Not Confirmed

              Update your events

              Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program

              Contact the Supplier

              Lead Product(s): NTX-001

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 14, 2020

              Details:

              U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Neuraptive's franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.

              PharmaCompass__DigitalAd